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Abstract
We present a successful case of thoracic endovascular aortic repair (TEVAR) for chronic Stanford type B aortic
dissection (B-AD) with recurrent ischemic colitis. The patient was a 56-year-old woman with abdominal pain as the
main complaint who had two operations previously: the total arch replacement 8 years ago and the Bentall 7 years
ago for acute Stanford type A aortic dissection. Her abdominal pain worsened as her blood pressure became low
during her hemodialysis treatment. An enhanced computed tomography scan was performed on the patient and
showed chronic B-AD that occurred from the distal anastomotic part of the total arch graft to the bilateral common
iliac arteries. The celiac artery and superior mesenteric artery (SMA) arose from the true lumen, and these were
compressed by the expanded false lumen. Her complicated chronic B-AD was treated with the Zenith Dissection
Endovascular System, and its procedure was performed as her proximal entry tear was covered by a proximal
tapered Zenith TX2 stent graft, supplemented by a noncovered aortic stent extending across both renal arteries,
the SMA, and the celiac artery. Seven days after this operation, enhanced computed tomography showed that the
patient’s true lumen was expanded and her blood flow to the true lumen and SMA was improved. On the other
hand, her false lumen tended to be thrombosed. Consequently, she was discharged 10 days after the operation
without any postoperative complications as she had no abdominal complaints even though she underwent
hemodialysis three times per week after the operation. We believe that TEVAR supplemented by a noncovered
aortic stent is an effective treatment, even for highly chronic B-AD in dialysis patients.
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Background
Endovascular techniques and devices have recently
been developed for the management of aortic dissection
[1–3]. Recently, the INSTEAD-XL study showed that
thoracic endovascular aortic repair (TEVAR) can improve
the survival rate of up to 5 years for aorta-specific cases
and delayed the disease progression of stable Stanford type
B aortic dissection (B-AD) with suitable anatomy [4, 5]
even though B-AD can be complicated by various symp-
toms such as uncontrollable hypertension, aortic rupture,
and end-organ ischemia [4, 5]. However, the effectiveness
of TEVAR for such complicated chronic B-AD of patients
is still an ongoing debate. Additionally, patients with end-
stage renal failure (ESRF) on hemodialysis have many ath-
erosclerotic comorbidities including ischemic colitis [6].
We present here a rare case of chronic B-AD in a dialy-
sis patient. The patient had been followed up for 8 years
and developed ischemic colitis repeatedly along with
hypotension due to hemodialysis. We performed TEVAR
with a noncovered aortic stent for this complicated
chronic B-AD.
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Case presentation
The patient was a 56-year-old woman with recurrent
abdominal pain as the main complaint and who had
been on maintenance hemodialysis of ESRF for 26 years.
She had the operations of total arch replacement 8 years
ago and a Bentall 7 years ago for acute Stanford type A
aortic dissection. Although dissections still remained
on the descending thoracic and abdominal aorta from
the previous two operations, the diameter of the aorta
remained stable without its enlargement. Therefore, she
underwent conservative treatments.
Her initial abdominal pain with ischemic colitis oc-
curred 1 year ago, and colonoscopy was performed. By
the diagnosis of the colonoscopy, we found a white
coating in the vicinity of the Bauhin valve and localized
distorted ulcers in the ascending colon. However, mu-
cosal necrosis was not found (Fig. 1). Since her symp-
toms were slight and temporary, she remained on
conservative treatments at that time. Her abdominal
pain became worse; melena occurred often during the
course of her conservative treatments, and these symp-
toms occurred when blood pressure became low under
hemodialysis. Then, she was referred to our hospital for
further evaluation of her recurrent ischemic colitis.
Computed tomography (CT) scans showed chronic B-
AD, which extended from the distal anastomotic part of
the total arch graft to both common iliac arteries. The
distal re-entry size was 26 mm. The expanded false
lumen compressed the true lumen of most of the aorta,
including the origin of the superior mesenteric artery
(SMA) (Fig. 2).
Based on these clinical findings, we considered that
this recurrent ischemic colitis was a result of diminished
blood flow to the SMA due to the compressed true
lumen combined with hypotension due to hemodialysis.
We then determined that therapeutic enlargement of the
true lumen would improve blood flow to the SMA and
reduce the risk of ischemic colitis. For treatment, we de-
cided to perform TEVAR because open surgical repair
can be risky for the patient considering the history of
previous Bentall operation and comorbid ESRF. Be-
cause the patient’s quality of life was adversely affected
by recurrent ischemic colitis, she agreed to undergo the
procedure we suggested, and informed consent was ob-
tained. The operation was performed under general
anesthesia. An incision was made in the right groin to
expose the right femoral artery. A 6Fr sheath intro-
ducer was inserted percutaneously from the left com-
mon femoral artery for aortography. A 8Fr sheath
introducer was inserted from the right exposed com-
mon femoral artery, and we delivered a guidewire and
catheter with contrast radiography to pass into the
compressed true lumen. The proximal entry tear in the
patient was covered by a Zenith TX2 stent graft (diam-
eter, 32–28 mm; mean length, 200 mm; Cook Medical,
Bloomington, IN), supplemented by a noncovered aor-
tic stent (TXD; diameter, 36 mm; length, 164 mm;
Cook Medical) around both renal arteries, the SMA,
and the celiac artery (CA). The TX2 was deployed just
distal to the left subclavian branch to seal the entry tear
(Fig. 3a). The noncovered aortic stent (TXD) was de-
ployed from above the CA to under both renal arteries
to expand the true lumen and to improve blood flow of
the CA and SMA (Fig. 3b). The operation time was 2 h
and 33 min, and blood loss was 150 cc. The patient tol-
erated these procedures well and was transferred to the
postoperative care unit in a hemodynamically stable
condition. Her bowel condition improved just after the
operation.
Seven days after the operation, CT showed improved
blood flow in the true lumen, CA, and SMA, and the
false lumen tended to be thrombosed (Fig. 4). She was
discharged 10 days after the operation without any post-
operative complications. She then underwent hemodialysis
three times per week after the operation, but her abdom-
inal pain following hypotension due to hemodialysis had
completely disappeared. She remained well for 6 months
after the operation.
Fig. 1 a A white coating could be seen in the vicinity of the Bauhin valve. b Localized distorted ulcers could be seen in the ascending colon. Mucosal
necrosis was not found
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Discussion
We experienced successful TEVAR for complicated chronic
B-AD. The patient had ischemic complications 8 years
after the conservative treatments for chronic B-AD.
This clinical course is rare because it took a long period
of 8 years for ischemic colitis to appear after the occur-
rence of B-AD [7]. Furthermore, the occurrence of is-
chemic colitis on this patient was not easily recognized
solely through the history of hemodialysis-dependent
ESRF. Ischemic colitis is a well-known complication of
ESRF [8], and abdominal pain after hemodialysis can
then often occur because of hypovolemia. Preoperatively,
in our patient, we observed that ischemic colitis under
hemodialysis was coincidentally worsened by chronic B-
AD. Interestingly, however, the abdominal ischemic symp-
toms disappeared completely after TEVAR. This clinical
course suggested that the ischemic colitis was mainly
caused by chronic B-AD and the relative hypovolemia fol-
lowing hemodialysis which had worsened the ischemic
condition. Therefore, physicians should carefully evaluate
Fig. 2 The true lumen (T) and superior mesenteric artery (SMA) were compressed by the expanded false lumen (F). a Sagittal slice, b axial slice at
the level of bronchial bifurcation, and c axial slice at the level of the SMA. T true lumen, F false lumen
Fig. 3 a The TX2 was deployed just distal to the left subclavian branch to seal the entry of the false lumen. b The TXD was deployed at the SMA
to expand the true lumen and improve blood flow of the SMA
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the effect of stable chronic B-AD on ischemic colitis
considering ischemic colitis may take a long period of
time to appear after chronic B-AD and diagnosis of
ischemic colitis is difficult.
With regard to treatment of B-AD, TEVAR is less in-
vasive and an effective treatment compared with open
surgery [9]. Fattori et al. demonstrated that operative
mortality and complications were 33.9 and 40 % in open
surgery compared with 10.6 and 20 % in TEVAR, re-
spectively [10]. Hogendoorn et al. also reported that the
30-day mortality rate was 17.5 % in open surgery and
10.2 % in TEVAR [11]. In addition, TEVAR has better
aorta-specific survival and delayed disease progression
than conservative treatment [3]. Currently, TEVAR is a
good treatment option for B-AD and is expected to be
effective, even for complicated cases.
In the present case, the purpose of surgical treatment
was to expand the true lumen and improve blood flow
into the SMA. No aortic dilatation or rapid expansion
was found in our case. We considered that our patient
had many risks for surgical treatment because of her
comorbidities. Therefore, we performed TEVAR with
the TX2 in the proximal site to seal the entry tear and
the TXD was deployed at the SMA to expand the true
lumen and improve blood flow in the SMA. We did not
expect that TEVAR above the CA could demonstrate the
proper radial force to expand the true lumen below the
CA because the dissection had occurred 8 years ago and
the vessel wall could be highly sclerotic. In our case,
organ ischemia was severe enough that an improvement
of SMA blood flow was required. With regard to the dis-
tal site, the TXD which was composed of a noncovered
aortic stent contributed to maintaining the opening of
the origin of the SMA. At the same time, use of a bare
metal stent allowed the remaining flow to the false lumen.
In general, such endoleak is a risk for progression of aortic
dilatation. TEVAR sometimes causes retrograde aortic
dissection, which often requires immediate open surgical
repair [12]. Therefore, covering the true lumen and ex-
tending into the thoracoabdominal aorta with a noncov-
ered aortic stent to diminish retrograde endoleak could be
important. In addition, flow to the artery of Adamkiewicz
could contribute to prevent acute vertebral ischemia.
In our patient, TEVAR supplemented with a noncov-
ered aortic stent was successful as the initial procedure.
However, the long-term outcome is also important. The
purpose of TEVAR for chronic B-AD includes not only
improving prognosis but also preventing future surgical
intervention of aortic dilatation [13]. Physicians need to
be aware of other complications of TEVAR, such as
stent-graft collapse, stent-graft migration, stent-graft tor-
sion, aortoesophageal fistula, mobile thrombus within
the stent-graft lumen, aneurysm formation, and late rup-
ture. These complications warrant the importance of
close and lifelong imaging follow-up of these patients
[12]. Therefore, after TEVAR for B-AD, patients should
be carefully followed up to identify any complications.
Conclusions
We present a rare case of chronic B-AD with unique is-
chemic colitis, which worsened following hypotension
due to hemodialysis. Our treatment with TEVAR supple-
mented with a noncovered aortic stent was successful.
We believe that TEVAR is a good treatment option, even
Fig. 4 Blood flow of the true lumen and SMA was improved. The false lumen remained but tended to be thrombosed. a Sagittal slice, b axial
slice at the level of bronchial bifurcation, and c axial slice at the level of the SMA. T true lumen, F false lumen
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for complicated chronic B-AD, including especially chronic
cases or cases causing organ ischemia. Further studies are
required to validate the optimal indication and effective-
ness of TEVAR for complicated chronic B-AD.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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